Box and IBM Partner to Bring New Enterprise-Level AI Models to Support Content Generation and Productivity
REDWOOD CITY, Calif & ARMONK, N.Y.--(BUSINESS WIRE)--Box, Inc. (NYSE: BOX), the leading Intelligent Content Management (ICM) platform, and IBM (NYSE: IBM) today announced they are partnering to help organizations accelerate the adoption of enterprise-level AI for content-driven workflows using IBM watsonx and Box AI. Additionally, Box is using IBMwatsonx.governance internally for life-cycle management of AI models to monitor, govern and provide guardrails for various regulations.
Box and IBM partner to bring new enterprise-level AI models to support content generation and productivity
Share
The majority of an organization's data is often unstructured — buried within contracts, spreadsheets, presentations and more. This data can be highly valuable for AI, but often highly sensitive. Building a trusted technology pipeline for AI to access this data can be essential for security and compliance efforts, particularly in highly regulated industries.
Box customers now have the option of leveraging Box AI with IBM watsonx to help unlock the value of their enterprise content and data. The solution uses IBM's enterprise AI studio, watsonx.ai, to deliver a selection of models for Box AI – including the open-source, IBM Granite models and the latest Meta Llama models. Infusing AI capabilities into business process automation and content management can help organizations tackle a wide range of AI-driven use cases such as data extraction, automated document processing and content analysis. IBM is using Box AI with IBM watsonx within its own workforce today, and Box is now making this solution available to other enterprise customers.
'The impact AI is having on the enterprise is unlike anything we've seen since the birth of the internet,' said Aaron Levie, co-founder and CEO of Box. "Traditionally, knowledge work has been constrained by the time it takes to research, create and review content — but AI changes that, accelerating these processes exponentially. By deepening our partnership with IBM and leveraging watsonx, we're empowering enterprises to harness AI responsibly and at scale."
'Organizations are seeking purpose-built AI solutions that empower their teams to make faster, data-driven decisions,' said Rob Thomas, Senior Vice President, Software and Chief Commercial Officer, IBM. 'Our partnership with Box enables businesses to seamlessly integrate AI into their core processes, helping to enhance productivity and transform operations.'
Additionally, Box has deployed IBM watsonx.governance internally to help address responsible AI deployment across its model lifecycles, from development to production. It is designed to assist Box address risk, compliance obligations and the AI lifecycle, helping AI-driven insights remain auditable. Box also continues using Red Hat OpenShift, the industry's leading hybrid cloud application platform powered by Kubernetes, which enables Box to support faster, scalable AI application development and deployment across cloud environments, helping to deliver secured and efficient AI-driven workflows on pace with evolving enterprise needs and technological innovation.
IBM has enabled Box AI with IBM watsonx to elevate employee productivity within its own workforce, providing them with seamless interaction directly with their Box content. With Box AI, IBMers experience how partners embed watsonx into their own solutions and bring IBM technology to clients across industry.
Box AI with IBM watsonx is now available to Box Enterprise Advanced customers via Box AI Studio and Box AI APIs. IBM is a Box authorized reseller, and customers buying Box products that include Box AI through IBM will be equipped with IBM's flagship family of AI models built for business, enabling a seamless experience. Learn more about how Box AI with IBM watsonx will transform the way you work with your content at IBM Think, May 5-8 and Box's Content + AI Summit on May 15, 2025.
About Box
Box (NYSE:BOX) is the leader in Intelligent Content Management. Our platform enables organizations to fuel collaboration, manage the entire content lifecycle, secure critical content, and transform business workflows with enterprise AI. Founded in 2005, Box simplifies work for leading global organizations, including AstraZeneca, JLL, Morgan Stanley, and Nationwide. Box is headquartered in Redwood City, CA, with offices across the United States, Europe, and Asia. Visit box.com to learn more. And visit box.org to learn more about how Box empowers nonprofits to fulfill their missions.
About IBM
IBM is a leading provider of global hybrid cloud and AI, and consulting expertise. We help clients in more than 175 countries capitalize on insights from their data, streamline business processes, reduce costs and gain the competitive edge in their industries. More than 4,000 government and corporate entities in critical infrastructure areas such as financial services, telecommunications and healthcare rely on IBM's hybrid cloud platform and Red Hat OpenShift to affect their digital transformations quickly, efficiently and securely. IBM's breakthrough innovations in AI, quantum computing, industry-specific cloud solutions and consulting deliver open and flexible options to our clients. All of this is backed by IBM's long-standing commitment to trust, transparency, responsibility, inclusivity and service.
Visit www.ibm.com for more information.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
23 minutes ago
- Yahoo
BofA outlines the bull and bear arguments surrounding IBM shares
- Shares in International Business Machines (NYSE:IBM) has surged so far this year, spurred on by hopes around the software group's artificial intelligence ambitions. IBM has said that it now has a "book of business" for its ChatGPT-like generative AI that is worth $6 billion, while CEO Arvind Krishna has said that customer interest in utilizing different AI models would likely fuel demand in the future. The company has also been specializing in developing tools that allow clients to build out their own AI-enhanced agents. Speaking to Reuters in May, Krishna suggested that, using IBM's Granite suite of AI models, along with alternatives from Mistral and Facebook-owner Meta Platforms (NASDAQ:META), these agents could be constructed in mere minutes. These capabilities will lead to an acceleration of the rate of growth of its AI operations, Krishna said at the time. The comments came after IBM announced in April that it would invest some $150 billion in the United States, where it has long had a presence as a manufacturer of mainframe computers. Krishna noted that quantum computers -- a new type of computer that harnesses quantum mechanics to carry out tasks -- will also be made in the country. "There's going to be a very healthy market that behooves us to invest and lean in," Krisna told Reuters. Yet, even as optimism surrounds IBM's AI ambitions, a murky economic outlook clouded its most recent earnings. Faced with the looming threat of sweeping U.S. tariffs, analysts have warned that many companies may be reining in spending, potentially weighing on IBM's key consulting arm. A push by U.S. President Donald Trump's administration to slash government spending has also led to the shelving of 15 federal contracts at IBM that accounted for $100 million in business. Revenue from the consulting segment slipped in the most recent quarter by 2%, although IBM backed its 2025 target for top-line growth on a constant currency basis of at least 5%. Writing in a note to clients, analysts at BofA led by Wamsi Mohan said that IBM shares, despite trading at all-time highs, are "interesting due to the transformational initiatives undertaken by management." "IBM underwent a significant transformation over the last five years by shifting their software segment towards strategic M&A investments, shedding lower growth/high cost businesses, and rebalancing their portfolio towards cloud and AI trends," the brokerage wrote. However, they flagged that less rosy assessments of the stock have highlighted that IBM is "structurally under-owned and underweight." "This disconnect stems from the underperformance from 2010-2019 as revenues, margins and free cash flow were under pressure. While the turnaround [from 2020-2025] is acknowledged by bears, the valuation relative to growth profile remains a hurdle for many," the analysts said. Weighing these arguments, the BofA strategists lifted their price target for the stock to $320 from $290 and reiterated their "buy" rating of the stock. Related articles BofA outlines the bull and bear arguments surrounding IBM shares UBS identifies key thematic opportunities for stock market investors This sector is uniquely positioned to capture infrastructure spend growth: analyst Sign in to access your portfolio
Yahoo
42 minutes ago
- Yahoo
2 High-Yield Healthcare Dividend Stocks to Buy Hand Over Fist in June
The average healthcare stock has a yield of just 1.7%. Medtronic's dividend yield is 3.3%. Alexandria Real Estate Equities' yield is 7.4%. 10 stocks we like better than Medtronic › The healthcare sector isn't exactly known for offering huge yields, with Health Care Select Sector SPDR (NYSEMKT: XLV) offering a yield of just 1.7%. If dividend investors take some time to dig into the sector, however, they can do much better. For example, Medtronic (NYSE: MDT) has a 3.3% yield today, and Alexandria Real Estate Equities (NYSE: ARE) is offering a yield of 7.4%. Here's what you need to know about each of these high-yield healthcare stocks. Medtronic makes medical devices. It is one of the largest competitors in the space, making products across the cardiovascular, neuroscience, medical surgical, and diabetes categories. It has a leading position in each of the areas in which it operates, and it operates on a global scale. That said, the last few years haven't been the best ones for the company. Innovation, which is highly important in the healthcare space, can be lumpy. And given Medtronic's size, the business has become a little cumbersome. Growth has stalled out, and profitability has come under pressure. Investors have focused on the negatives pushing the shares lower and the dividend yield up toward the high end of Medtronic's historical yield range. If you are a dividend investor that thinks in decades and not days, however, this is likely to be an investment opportunity. The company's innovation pipeline is starting to turn into new-product introductions. As new products gain traction, financial performance is likely to improve. And management has been working to streamline the business with cost cuts and a move to refocus on its most profitable operations. To that end, the company is set to spin off its lower-margin diabetes division in 2026. The move is expected to be immediately accretive to earnings, and the dividend policy isn't expected to change. All in, Medtronic is doing what it needs to do to get back on the growth path. And that should support continued dividend increases; the medical device maker only has two years to go before it hits Dividend King status (50+ years of annual dividend increases). June could be an opportune time to buy the stock hand over fist. Alexandria is a real estate investment trust (REIT), which seems pretty far away from healthcare. Its primary focus is on office properties, which also seems a bit removed from healthcare. The key here is that the REIT owns biomedical research facilities, which combine research space and office space in one property. Both are important to each other since the research takes place in specialized space, while the analysis of that research takes place in a normal office environment. Alexandria is one of the largest pure play medical research REITs you can buy. Alexandria counts some of the largest and most important medical research groups as tenants, from both the private side of the equation and the government side. However, like any landlord, the REIT's revenues will be impacted by the occupancy levels of its properties. And those rise and fall over time. Right now, occupancy is relatively weak, dropping to 91.7% at the end of the first quarter of 2025 from 94.6% at the end of 2024. Swings like this happen from time to time, but Wall Street is treating Alexandria as if its dividend is at a material risk of being cut. Only the funds from operations (FFO) payout ratio in the first quarter was a fairly strong 57%. There's room for adversity before a dividend cut would be in order. To be fair, office properties, and particularly highly specialized office properties, tend to have higher operating costs than other real estate assets. But it seems highly likely that Alexandria will manage its way through this weak patch and continue to extend its 15-year streak of annual dividend increases. For income lovers, this healthcare REIT is worth a deep dive in June. The average healthcare stock has an uninspiring dividend yield. But the average is made up of many different companies, some of which actually have very attractive dividend yields. That list includes industry-leading companies like Medtronic and Alexandria Real Estate. You might just want to pick up shares in one, or both, of these high yielders before June is over after you get to know them a little better. Before you buy stock in Medtronic, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Medtronic wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $664,089!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $881,731!* Now, it's worth noting Stock Advisor's total average return is 994% — a market-crushing outperformance compared to 172% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 9, 2025 Reuben Gregg Brewer has positions in Medtronic. The Motley Fool has positions in and recommends Alexandria Real Estate Equities. The Motley Fool recommends Medtronic and recommends the following options: long January 2026 $75 calls on Medtronic and short January 2026 $85 calls on Medtronic. The Motley Fool has a disclosure policy. 2 High-Yield Healthcare Dividend Stocks to Buy Hand Over Fist in June was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
5 hours ago
- Yahoo
Is AbbVie the Best Dividend Stock in Big Pharma Today?
AbbVie Inc. (NYSE:ABBV) is one of the best dividend stocks for a bear market. The company holds the title of a Dividend King, having raised its dividend for 52 straight years. That kind of track record makes a dividend cut highly unlikely, as it would break the streak and potentially take decades to regain entry into this elite group. A pharmacist handing out a pharmaceutical drug to a patient in a drug store or chemist. AbbVie Inc. (NYSE:ABBV) is a leading pharmaceutical company with a strong product lineup that consistently delivers solid revenue and earnings. Its top growth drivers, Skyrizi and Rinvoq, have outperformed expectations, leading management to raise their combined 2027 sales forecast to over $31 billion. The company also benefits from other key products like Botox and a deep pipeline of new therapies to offset future patent expirations. With strong cash flow and a reliable portfolio, AbbVie Inc. (NYSE:ABBV) remains an attractive pick for income investors looking for long-term dividend stability. Naturally, if AbbVie encounters serious challenges, it could be pressured to reduce its dividend. One concern is its elevated payout ratio, currently at 267.66%. Typically, when a company's payout ratio remains above 70% for an extended time, it raises the risk of a dividend cut or suspension. However, AbbVie Inc. (NYSE:ABBV)'s next-generation immunology drugs are seeing strong growth, which could help offset the challenges it's facing from Humira. The rheumatoid arthritis treatment has been under pressure due to its loss of market exclusivity in the US and the increasing competition from biosimilars. ABBV currently offers a dividend yield of 3.5%, which is above S&P's average dividend yield of 1.3%. While we acknowledge the potential of ABBV as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: and Disclosure. None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
